227 related articles for article (PubMed ID: 29546433)
1. Cost-effectiveness of indacaterol/glycopyrronium in comparison with salmeterol/fluticasone combination for patients with moderate-to-severe chronic obstructive pulmonary disease: a LANTERN population analysis from Singapore.
Tee A; Chow WL; Burke C; Guruprasad B
Singapore Med J; 2018 Jul; 59(7):383-389. PubMed ID: 29546433
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting.
Price D; Keininger D; Costa-Scharplatz M; Mezzi K; Dimova M; Asukai Y; Ställberg B
Respir Med; 2014 Dec; 108(12):1786-93. PubMed ID: 25307414
[TBL] [Abstract][Full Text] [Related]
3. Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease: Analyses Conducted for Canada, France, Italy, and Portugal.
Reza Maleki-Yazdi M; Molimard M; Keininger DL; Gruenberger JB; Carrasco J; Pitotti C; Sauvage E; Chehab S; Price D
Appl Health Econ Health Policy; 2016 Oct; 14(5):579-94. PubMed ID: 27516088
[TBL] [Abstract][Full Text] [Related]
4. Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population.
Bjermer L; van Boven JFM; Costa-Scharplatz M; Keininger DL; Gutzwiller FS; Lisspers K; Mahon R; Olsson P; Roche N
Respir Res; 2017 Dec; 18(1):206. PubMed ID: 29228950
[TBL] [Abstract][Full Text] [Related]
5. Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone in Patients with COPD-A Cost-Effectiveness Analysis in the Czech Republic.
Skoupa J; Kasak V; Klimes J; Valena T
Value Health Reg Issues; 2018 Sep; 16():112-118. PubMed ID: 30539739
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD.
Chan MC; Tan EC; Yang MC
Int J Chron Obstruct Pulmon Dis; 2018; 13():1079-1088. PubMed ID: 29670344
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Indacaterol/Glycopyrronium (IND/GLY) Versus Salmeterol/Fluticasone in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: The Chinese Cohort from the LANTERN Study.
Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Patalano F; Banerji D
COPD; 2016 Dec; 13(6):686-692. PubMed ID: 27715335
[TBL] [Abstract][Full Text] [Related]
8. Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study.
Wedzicha JA; Zhong N; Ichinose M; Humphries M; Fogel R; Thach C; Patalano F; Banerji D
Int J Chron Obstruct Pulmon Dis; 2017; 12():339-349. PubMed ID: 28176893
[TBL] [Abstract][Full Text] [Related]
9. Real-life effectiveness of indacaterol-glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study.
Kaplan A; Chapman KR; Anees SM; Mayers I; Rochdi D; Djandji M; Préfontaine D; McIvor A
Int J Chron Obstruct Pulmon Dis; 2019; 14():249-260. PubMed ID: 30718952
[TBL] [Abstract][Full Text] [Related]
10. Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis.
Vogelmeier C; Zhong N; Humphries MJ; Mezzi K; Fogel R; Bader G; Patalano F; Banerji D
Int J Chron Obstruct Pulmon Dis; 2016; 11():3189-3197. PubMed ID: 28008244
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US.
Rajagopalan K; Bloudek L; Marvel J; Dembek C; Kavati A
Int J Chron Obstruct Pulmon Dis; 2018; 13():3867-3877. PubMed ID: 30568438
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial.
Frith PA; Ashmawi S; Krishnamurthy S; Gurgun A; Hristoskova S; Pilipovic V; Hamann AM; Backer A; Olsson P; Kostikas K; Diaz DV;
Respirology; 2018 Dec; 23(12):1152-1159. PubMed ID: 30074294
[TBL] [Abstract][Full Text] [Related]
13. Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study.
Anzueto AR; Kostikas K; Mezzi K; Shen S; Larbig M; Patalano F; Fogel R; Banerji D; Wedzicha JA
Respir Res; 2018 Jun; 19(1):121. PubMed ID: 29925383
[TBL] [Abstract][Full Text] [Related]
14. Modelling the Cost-Effectiveness of Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone Using a Novel Markov Exacerbation-Based Approach.
Lakhotia B; Mahon R; Gutzwiller FS; Danyliv A; Nikolaev I; Thokala P
Int J Chron Obstruct Pulmon Dis; 2020; 15():787-797. PubMed ID: 32368025
[TBL] [Abstract][Full Text] [Related]
15. The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD.
Anzueto AR; Vogelmeier CF; Kostikas K; Mezzi K; Fucile S; Bader G; Shen S; Banerji D; Fogel R
Int J Chron Obstruct Pulmon Dis; 2017; 12():1325-1337. PubMed ID: 28496316
[TBL] [Abstract][Full Text] [Related]
16. Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study.
Wedzicha JA; Singh D; Tsiligianni I; Jenkins C; Fucile S; Fogel R; Shen S; Goyal P; Mezzi K; Kostikas K
Respir Res; 2019 Jan; 20(1):4. PubMed ID: 30621717
[TBL] [Abstract][Full Text] [Related]
17. Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study.
Vogelmeier CF; Chapman KR; Miravitlles M; Roche N; Vestbo J; Thach C; Banerji D; Fogel R; Patalano F; Olsson P; Kostikas K; Wedzicha JA
Int J Chron Obstruct Pulmon Dis; 2018; 13():1125-1134. PubMed ID: 29692607
[TBL] [Abstract][Full Text] [Related]
18. Cost-Utility Analysis of Fixed-Dose Combination of Indacaterol Acetate Glycopyrronium Bromide and Mometasone Furoate as a Maintenance Treatment in Adult Patients with Asthma Not Adequately Controlled with a Maintenance Combination of a Long-Acting Beta-Agonist and a High Dose of an Inhaled Corticosteroid Who Experienced One or More Asthma Exacerbations in the Previous Year.
Mangia PP; Gallo O; Ritrovato D; Pradelli L
Clin Drug Investig; 2021 Sep; 41(9):785-794. PubMed ID: 34333742
[TBL] [Abstract][Full Text] [Related]
19. Response to Indacaterol/Glycopyrronium (IND/GLY) by Sex in Patients with COPD: A Pooled Analysis from the IGNITE Program.
Tsiligianni I; Mezzi K; Fucile S; Kostikas K; Shen S; Banerji D; Fogel R
COPD; 2017 Aug; 14(4):375-381. PubMed ID: 28594587
[TBL] [Abstract][Full Text] [Related]
20. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
